Clinical Trials Logo

Clinical Trial Summary

This is a single arm Phase II study, in which 6 cycles of durvalumab with chemotherapy (Etoposide and Cisplatin) and durvalumab followed by Sequential radiotherapy for limited stage small cell lung cancer.


Clinical Trial Description

Primary Outcome Measures: Progression free survival Secondary Outcome Measures: Overall survival Safety analysis ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05034133
Study type Interventional
Source Beijing Haidian Hospital
Contact Yuqing Huang, Director
Phone +8601082693152
Email huangyuqing555@gmail.com
Status Recruiting
Phase Phase 2
Start date September 1, 2021
Completion date August 31, 2024

See also
  Status Clinical Trial Phase
Completed NCT01935336 - Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers Phase 2
Recruiting NCT05443646 - Consolidation Serplulimab Following Concurrent Chemoradiotherapy for LS-SCLC Patients Phase 2
Completed NCT00066742 - Tirapazamine Combined With Chemo and RT in Limited-Stage Small Cell Lung Cancer Phase 2
Recruiting NCT04790253 - PRophylactic Cerebral Irradiation or Active MAgnetic Resonance Imaging Surveillance in Small-cell Lung Cancer Patients (PRIMALung Study) N/A
Recruiting NCT05942508 - A Phase Ib Study of TQB2450 Combined With Anlotinib in Patients With Limited Stage Small Cell Lung Cancer After First-line Radiotherapy and Chemotherapy Phase 1
Completed NCT00019006 - Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer Phase 1
Recruiting NCT05483543 - Pamiparib for Consolidation Treatment of Unprogressed LS-SCLC After Concurrent Chemoradiotherapy Phase 2
Active, not recruiting NCT02046733 - Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease Phase 2
Completed NCT04952597 - Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer Phase 2
Recruiting NCT05623267 - Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT Phase 2/Phase 3
Completed NCT01457469 - Enhanced Quitline Intervention in Smoking Cessation for Patients With Non-Metastatic Lung Cancer Phase 1
Recruiting NCT06117774 - Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Phase 3
Completed NCT01999881 - Impacts of Exercise on Prognostic Biomarkers in Lung Cancer Patients N/A
Not yet recruiting NCT05496166 - The Efficiency of Surgery and Radiotherapy After SHR-1316 (Adebrelimab) and Platinum-containing Doublet Induction Therapy for Limited-stage Small Cell Lung Cancer Phase 3
Recruiting NCT04829708 - Efficacy and Safety of Prophylactic Cranial Irradiation Versus MRI Surveillance in Patients With Limited-stage Small Cell Lung Cancer Who Achieved Remission After First-line Chemoradiotherapy Phase 3
Completed NCT00470054 - Dasatinib in Treating Patients With Relapsed Small Cell Lung Cancer Phase 2
Terminated NCT00084487 - Rebeccamycin Analog as Second-Line Therapy in Treating Patients With Limited-Stage or Extensive-Stage Small Cell Lung Cancer That Relapsed After Previous First-Line Chemotherapy Phase 2
Recruiting NCT06256237 - Neoadjuvant Therapy With Toripalimab and JS004 Combined With Etoposide and Platinum Chemotherapy for Limited-stage Small Cell Lung Cancer : A Phase 2 Trial Phase 2